MXCT
MaxCyte, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.47
P/S
2.43
EV/EBITDA
-1.91
DCF Value
$-3.51
FCF Yield
-45.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.4%
Operating Margin
-131.9%
Net Margin
-135.1%
ROE
-24.1%
ROA
-22.1%
ROIC
-23.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $7.3M | $-9.6M | $-0.09 |
| FY 2025 | $33.0M | $-44.6M | $-0.42 |
| Q3 2025 | $6.8M | $-12.4M | $-0.12 |
| Q2 2025 | $8.5M | $-12.4M | $-0.12 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.45
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.